Shares of Capricor Therapeutics (NASDAQ:CAPR) plunged about 13% after the company initiated litigation against Nippon Shinyaku Co., Ltd. and its U.S. subsidiary NS Pharma Inc., challenging their distribution arrangement for Deramiocel, an investigational cell therapy being evaluated for Duchenne muscular dystrophy. Nippon Shinyaku shares fell as much as 15% following the filing.
In its complaint, Capricor contends that NS Pharma did not sufficiently prepare for the commercial launch of Deramiocel. The company also claims that a pricing mechanism embedded in the distribution agreement would effectively prevent patients covered by Medicare, Medicaid or private insurers from obtaining the therapy, prompting Capricor to seek rescission of the agreement.
Capricor has moved for a preliminary injunction aimed at preserving its ability to distribute Deramiocel to patients while the Food and Drug Administration completes its review. The FDA has granted the therapy Priority Review and set a target PDUFA action date of August 22, 2026.
The complaint says Capricor tried to address the pricing concerns through good-faith negotiations, but that NS Pharma refused to compromise. Separately, Capricor is preparing commercial readiness plans in the event the FDA approves the therapy.
Duchenne muscular dystrophy is a progressive, fatal genetic disorder that affects about 15,000 people in the United States, primarily boys and young men. The company framing the dispute has emphasized access and pricing issues as central to its legal challenge.
Context and commercial readiness focus
The lawsuit centers on two operational claims: inadequate preparation for launch and contractual pricing terms that Capricor says would limit patient access. Capricor's parallel actions - seeking to rescind the distribution agreement and requesting a preliminary injunction - are intended to protect its ability to deliver the investigational therapy to patients pending regulatory outcome.
With Priority Review in place and a target FDA decision date of August 22, 2026, the dispute introduces a legal variable that could affect the pathway to commercialization and patient access if the agency approves the therapy.
Key points
- Capricor filed suit against Nippon Shinyaku and NS Pharma over their distribution agreement for Deramiocel, and its shares dropped roughly 13%.
- Capricor alleges NS Pharma was not sufficiently prepared for launch and that the agreement's pricing mechanism would block access for patients with Medicare, Medicaid or private insurance; Nippon Shinyaku shares fell up to 15%.
- The company has requested a preliminary injunction to preserve distribution ability pending FDA review; Deramiocel has Priority Review with a PDUFA target date of August 22, 2026.
Risks and uncertainties
- Legal outcome uncertainty - The court's decision on rescinding the distribution agreement or granting an injunction could materially affect distribution plans and timing for potential commercialization.
- Access and pricing dispute - If the pricing mechanism remains in effect, Capricor asserts it could prevent covered patients from obtaining the therapy, posing a risk to market access frameworks for the product.
- Regulatory timing - While the FDA has set a PDUFA target date, the ultimate approval decision and any conditions attached would determine whether Capricor's commercial readiness plans are actionable.
Market impact
Equity markets reacted to the legal filing with Capricor's shares tumbling and Nippon Shinyaku recording losses, reflecting investor concern over the dispute's implications for commercialization and patient access.